In-Q-Tel has invested in and partnered with Kailos Genetics to help the biotechnology company further develop sequencing technologies that will have potential use in the intelligence community.
Kailos said Tuesday it aims to continue development work on a next-generation sequencing laboratory and software platforms through the strategic partnership.
Tom Gillespie, an investment partner at In-Q-Tel, said that Kailos’ efforts to combine genomic technologies can offer advantages for the public and private sectors.
Troy Moore, chief scientific officer of Kailos Genetics, noted the partnership will also look to develop new systems to identify genetic materials.
Huntsville, Alabama-based Kailos has developed next-generation sequencing platforms that integrate target enrichment chemistries with proprietary analysis and reporting software.